JPRN-UMIN000013045尚未招募2 期
Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients. - Patient preference trial comparing capecitabine and S-1 in metastatic breast cancer patients.
Japan Breast Cancer Research Network0 个研究点目标入组 60 人开始时间: 2014年2月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 25years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •ECOG performance status is more than 3
研究者
相似试验
已完成
不适用
Randomised phase II study comparing capecitabine with oral cyclophosphamide and capecitabine in patients with advanced breast cancerAdvanced breast cancerCancerBreast cancerISRCTN68662102Cancer Trials New Zealand (CTNZ) (New Zealand)82
进行中（未招募）
不适用
Tesetaxel, an oral taxane, and capecitabine versus placebo and capecitabine in gastric cancerHistologically or cytologically confirmed gastric carcinoma, including gastric or gastroesophageal-junction adenocarcinomaMedDRA version: 14.1Level: LLTClassification code 10017760Term: Gastric cancer NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022164-12-DEGenta Incorporated580
已完成
不适用
A randomized controlled trial comparing capecitabine 5-days-on/2-days-off regimen with conventional regimen in stage II and III colorectal cancer.StageII(high risk) and stageIII resectable colorectal cancerJPRN-UMIN000032865Wakayama Medical University110
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern
进行中（未招募）
不适用
A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer - NDAdvanced or metastatic head and neck cancerLevel: HLTClassification code 10024530EUCTR2006-003775-13-ITOSPEDALE ONCOLOGICO DI BARI43